Atria Investments Inc Sells 378 Shares of Balchem Co. (NASDAQ:BCPC)

Atria Investments Inc lessened its stake in shares of Balchem Co. (NASDAQ:BCPC) by 14.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,330 shares of the basic materials company’s stock after selling 378 shares during the quarter. Atria Investments Inc’s holdings in Balchem were worth $380,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Westside Investment Management Inc. bought a new position in shares of Balchem during the 3rd quarter worth about $27,000. R Squared Ltd bought a new position in shares of Balchem during the 4th quarter worth about $29,000. Wilmington Savings Fund Society FSB bought a new position in shares of Balchem during the 3rd quarter worth about $35,000. Venturi Wealth Management LLC bought a new position in shares of Balchem during the 4th quarter worth about $95,000. Finally, Smartleaf Asset Management LLC boosted its position in shares of Balchem by 230.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 645 shares of the basic materials company’s stock worth $106,000 after purchasing an additional 450 shares in the last quarter. Institutional investors own 87.91% of the company’s stock.

Balchem Price Performance

Shares of NASDAQ BCPC opened at $167.72 on Monday. Balchem Co. has a fifty-two week low of $137.69 and a fifty-two week high of $186.03. The firm’s 50-day simple moving average is $163.84 and its 200 day simple moving average is $169.73. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.16 and a current ratio of 1.99. The stock has a market cap of $5.46 billion, a price-to-earnings ratio of 42.68, a PEG ratio of 4.41 and a beta of 0.63.

Balchem (NASDAQ:BCPC) last posted its earnings results on Friday, February 21st. The basic materials company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.11 by ($0.08). Balchem had a return on equity of 11.37% and a net margin of 13.47%. The firm had revenue of $240.00 million for the quarter, compared to the consensus estimate of $239.96 million. As a group, research analysts anticipate that Balchem Co. will post 4.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on BCPC shares. Sidoti raised shares of Balchem to a “hold” rating in a research report on Tuesday, February 25th. StockNews.com cut shares of Balchem from a “buy” rating to a “hold” rating in a research report on Tuesday, February 25th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $190.00 price target on shares of Balchem in a research report on Monday, February 24th.

Balchem Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.